Who
Sujata Tyagi Dayal
Director
Company insider
Files Form 4 as: Director, Emergent BioSolutions; Corporate V.P. and CCO, LVB Acquisition.
In numbers
- Trades disclosed
- 19
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $317K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 31 Jul 2012
- Last trade
- 1 May 2026
- Last filed
- 4 May 2026
Companies traded
Activity over time
1 Nov 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 May 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $107K12,781 at $8.36 | filing |
| 1 May 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $8,761980 at $8.94 | filing |
| 1 May 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $107K12,781 at $8.36 | filing |
| 1 May 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $8,761980 at $8.94 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —25,344 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,296 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,296 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —25,344 at $0.00 | filing |
| 7 Nov 2025filed 10 Nov 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $86K8,552 at $10.00 | filing |
| 30 Apr 2025filed 2 May 2025 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,824 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —34,403 at $0.00 | filing |
| 23 May 2024filed 28 May 2024 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,748 at $0.00 | filing |
| 23 May 2024filed 28 May 2024 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —17,430 at $0.00 | filing |
| 25 May 2023filed 30 May 2023 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —33,847 at $0.00 | filing |
| 21 Jul 2022filed 22 Jul 2022 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —11,852 at $0.00 | filing |
| 31 Jul 2012filed 2 Aug 2012 | LVB Acquisitionoption or derivative | SEC FORM 4 Code D | —180,000 | filing |
| 31 Jul 2012filed 2 Aug 2012 | LVB Acquisitionoption or derivative | SEC FORM 4 Code D | —40,000 | filing |
| 31 Jul 2012filed 2 Aug 2012 | LVB Acquisitionoption or derivative | SEC FORM 4 Code A | —180,000 | filing |
| 31 Jul 2012filed 2 Aug 2012 | LVB Acquisitionoption or derivative | SEC FORM 4 Code A | —110,000 | filing |
News
Comparing Monte Rosa Therapeutics (NASDAQ:GLUE) and Emergent Biosolutions (NYSE:EBS)EBS · tickerreport.com · 16 Oct 2026
0 headlines in the last 90 days name Sujata Tyagi Dayal; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.